Therefore, SIRPα-Fc-CD40L could bridge the macrophage-mediated phagocytosis of tumor cells to antigen-presenting cell (APC) activation and antigen presentation by two modes: (1) direct APC activation through CD40/CD40L, leading to antigen-specific CD8 stimulation and programmed immune memory, and (2) direct blocking of CD47 inhibition, resulting in enhanced tumor phagocytosis and increased antigen cross-presentation. Here, CD47 is linked to neoplasm.